Skip to content

ImmunityBio, Inc. IBRX Finance Lease Liability, Current

Finance Lease Liability, Current at other companies

Incyte logo
IncyteINCY
$4.41M-1.5%
Moderna logo
ModernaMRNA
$25M+8.7%
AbbVie logo
AbbVieABBV
$19M+11.8%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN

Other financials

Income statement

See full
Revenue$44.2M+168%
Gross profit$44.0M+167%
Operating income-$69.8M-8.3%
Net income-$632.8M-388%
EPS (diluted)-$0.62-313%

Balance sheet

See full
Cash & equivalents$205.2M+238%
Total debt$445.4M+32.2%
Total equity-$870.0M-47.1%
Total assets$646.6M+113%

Cash flow

See full
Operating cash flow-$75.4M+12.3%
CapEx$1.8M+58.4%
Free cash flow-$77.1M+11.4%

Valuation

See full
Market cap$7.71B+208%
Enterprise value$7.95B+187%
P/S54.7×-25.4×

Profitability

See full
Gross margin99.3%-0.5pp
Operating margin-185.4%-83.3pp
Net margin-606.2%-212pp
FCF margin-212%-95.8pp

Returns & leverage

See full
Return on equity-119.3%
Debt / equity0.1×
Current ratio6.7×+4.4×

Where this comes from

Reported directly by ImmunityBio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:FinanceLeaseLiabilityCurrent.

The official record: ImmunityBio, Inc.’s 10-K, filed February 23, 2026, on SEC EDGAR. View the filing →

Ask your AI about ImmunityBio, Inc.'s finance lease liability, current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ImmunityBio, Inc.'s finance lease liability, current?
ImmunityBio, Inc. (IBRX) reported finance lease liability, current of $52K in Q4 2025.
What does finance lease liability, current mean?
Finance lease liabilities (current) represent the portion of lease obligations that are due to be paid within the next twelve months. These obligations arise from long-term contracts where the company effectively controls the leased asset. This metric is critical for assessing near-term liquidity and cash flow requirements.